Isovalerylspiramycin Ⅰ alleviates liver injury and liver fibrosis by targeting the nucleotide-binding protein 2(NUBP2)-vascular non-inflammatory molecule-1(VNN1)pathway
10.1016/j.jpha.2024.101048
- Author:
Na ZHANG
1
;
Weixiao NIU
;
Weiping NIU
;
Yiming LI
;
Simin GUO
;
Yang LI
;
Weiqing HE
;
Hongwei HE
Author Information
1. NHC Key Laboratory of Biotechnology for Microbial Drugs,Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100050,China
- Publication Type:Journal Article
- Keywords:
Liver fibrosis;
Isovalerylspiramycin Ⅰ;
Carrimycin;
Nucleotide-binding protein 2;
Vascular non-inflammatory molecule-1
- From:
Journal of Pharmaceutical Analysis
2025;15(3):625-636
- CountryChina
- Language:English
-
Abstract:
Liver fibrosis is a vital cause of morbidity in patients with liver diseases and developing novel anti-fibrotic drugs is imperative.Isovalerylspiramycin Ⅰ(ISP Ⅰ)as a major component of carrimycin applied to upper respiratory infections,was first found to possess anti-fibrotic potential.The present study aims to evaluate the functions and mechanisms of ISP Ⅰ in protecting against liver fibrosis.According to our results,ISP Ⅰ not only reduced the expressions of fibrogenic markers in LX-2 cells but also appeared great protective effects on liver injury and liver fibrosis in bile duct ligation(BDL)rats and carbon tetrachloride(CCl4)mice.We proved that nucleotide-binding protein 2(NUBP2)was the direct target of ISP Ⅰ.ISP Ⅰ through targeting NUBP2,increased the amount of vascular non-inflammatory molecule-1(VNN1)on the cell membrane,which will inhibit oxidative stress and fibrosis.Simultaneously,the original carri-mycin's protective effect on liver damage and fibrosis was verified.Therefore,our study provides po-tential agents for patients with liver fibrosis-related diseases,and the clear mechanism supports wide application in the clinic.
